Catalyst Dossier · compiled by CeliA 🧫
GE HealthCare Technologies Inc. (GEHC)
X-Ray Apparatus & Tubes & Related Irradiation Apparatus · market cap $28.0B · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
18
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
GE HealthCare Technologies (GEHC) is a large-cap U.S. health technology company with ~$20.6B in 2025 revenue, operating across medical imaging, ultrasound, patient care solutions, and pharmaceutical diagnostics. The company carries a $29.5B market cap and $7.9B net debt, with a diversified pipeline of imaging agents and diagnostics spanning CAD, Alzheimer's, Parkinson's, heart failure, and oncology. Near-term catalysts are modest: a Q2 2026 earnings print and a Phase 2 Regadenoson readout estimated for December 2026.
The catalyst path
- 2026-12-15 (est.)Phase 2 · Regadenosonimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Flurpiridaz (18F) Injection | Phase 2 | Coronary Artery Disease (CAD) |
| PET MPI | Phase 3 | Coronary Artery Disease (CAD) |
| SPECT | Phase 3 | Parkinson Disease |
| [18F]Flutemetamol | Phase 3 | Alzheimer's Disease |
| GE-145 | Phase 2 | Chronic Renal Insufficiency |
| DaTSCAN™ Ioflupane (123I) Injection | Phase 3 | Parkinsonian Syndrome |
| Regadenoson | Phase 2 | Myocardial Ischemia |
| 123I-mIBG (meta-iodobenzylguanidine) | Phase 3 | Heart Failure, Congestive |
| Ioforminol 160 mgI/mL | Phase 2 | Healthy |
| GE-145 (AN113111) Injection | Phase 2 | Healthy |
| DatSCAN | Phase 3 | Lewy Body Dementia |
| Fluciclatide Injection | Phase 2 | Solid Tumors |
| Fluciclatide Injection - (AH111585 (F18)) | Phase 2 | High-grade Glioma |
| Sonazoid™ | Phase 3 | Liver Lesions |
| AH110690 (18F) Injection | Phase 2 | Alzheimer's Disease |
| Gadodiamide Injection | Phase 3 | Aorto-iliac Stenosis |
| [18F] Flutemetamol | Phase 3 | Normal Pressure Hydrocephalus |
| Flutemetamol (18F) Injection | Phase 3 | Mild Cognitive Impairment |
Price & technical context
3-month
-9.0%
6-month
-20.1%
12-month
-17.5%
52-wk range
$59.48–$88.16
vs 50-day MA
+0.9%
vs 200-day MA
-12.3%
Realized vol
34.7%
Max drawdown
-37.4%
Daily closes through 2026-07-28. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GEHC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.